Biocon gains as USFDA PAI at Bengaluru facility results in zero observations

Biocon gains as USFDA PAI at Bengaluru facility results in zero observations

Biocon Ltd. informed in a filing that the USFDA has conducted a pre-approval inspection (PAI) of an oral solid dosage manufacturing facility of Biocon Pharma Ltd., which was triggered by the submission of an ANDA.

The inspection of the Bengaluru facility took place between January 13-17, 2020. It resulted in zero observations and no Form 483 was issued.

Stock View:

Biocon Ltd is currently trading at Rs292.50 up by Rs2.05 or 0.71% from its previous closing of Rs290.45 on the BSE.

The scrip opened at Rs293.80 and has touched a high and low of Rs293.80 and Rs290.20 respectively. So far 9,98,631 (NSE+BSE) shares were traded on the counter.

The current market cap of the company is Rs34,854cr.




About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.

0 comments:

Post a Comment

Please add comment